GUMDROP : A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with metastatic Castrate-Resistant Prostate Cancer

Created by Channing Paller, last modified on Apr 14, 2012

Description:

This trial measures the effect of Tasquinimod on progression-free survival in patients with castrate-resistant prostate cancer. Eligible patients have evidence of bone metasteses; testosterone = 50 ng/dL; PSA progression (3 consecutive rises within 15 months, last PSA = 2.0 ng/mL) OR soft tissue metastases OR progressive  bone disease; Patients must have had NO prior chemotherapy within 2 years; and NO warfarin.

Link:

http://clinicaltrials.gov/ct2/show/NCT01234311

Site:

Johns Hopkins Hospital

Principal Investigator:

Michael Carducci, M.D.